Summary Urinary mucins which express determinants for the anti-breast carcinoma monoclonal antibody, 
High molecular weight glycoproteins, often described as mucins or mucin-like glycoproteins, are frequently found associated with breast carcinomas. These molecules have been identified as the target antigens for many monoclonal antibodies produced against breast carcinoma cells or human milk fat globule membranes (Burchell et al., 1983; Hilkens et al., 1984; Price et al., 1985; Sekine et al., 1985; Lan et al., 1987) . Such mucin antigens are clearly the products of normal epithelia and their secretions, as well as their malignant cell counterparts. The relevance of epithelial mucins to clinical studies in breast cancer is that they are detectable in the serum of patients and levels are particularly elevated in metastatic disease (reviewed in Kufe et al., 1988; Price, 1988) . Thus, there is intense interest in developing monoclonal antibody based assays for these products in the circulation in order that their clinical utility may be fully explored.
The monoclonal antibody, NCRC-l1, is one of those reagents produced against breast carcinoma cells which shows characteristic reactivity with tumours and normal glandular epithelia (Ellis et al., 1984) . However, this antibody belongs to the IgM immunoglobulin class which was considered to limit its clinical potential as a tumour targeting antibody. Therefore, the present investigation was initiated in an attempt to produce 'second generation' IgG monoclonal antibodies against mucin antigens bearing the NCRC-ll defined epitope. Since normal urine has been found to be an abundant source of epithelial mucin (Price et al., 1987a ) (presumably originating by exfoliation from the urothelium which reacts strongly with the NCRC-l1 antibody (Ellis et al., 1984) ), then urine was selected for antigen isolation by immunoadsorbent chromatography using immobilised NCRC-1 1 antibodies. One antibody, C595, raised against normal urinary epithelial mucin, was selected for further study and this has provided some insight into the nature of the antibody-defined determinants of these mucins.
Materials and methods
Monoclonal antibodies NCRC-l (IgM) was originally prepared using spleen cells from a Balb/c mouse immunised against dissociated breast carcinoma cells (Ellis et al., 1984) . The antibody C595 (IgG3) was prepared using spleen cells of a mouse immunised against NCRC-I 1-defined epithelial antigen isolated from normal urine. In the initial antibody screening tests, mass culture supernatants and supernatants from cloned hybridoma cells were selected for high reactivity against the immunising antigen preparation using a radioisotopic antiglobulin assay (Price et al., 1985) . This initial selection was followed by analyses of antibody reactivity with breast carcinoma tissue sections by immunocytochemistry.
NCRC-I I and C595 antibodies were purified by affinity chromatography using Sepharose-lentil lectin and Sepharoseprotein A columns (Pharmacia, Uppsala, Sweden), respectively.
The following murine antibodies were also used: C365 -IgGl (anti-carcinoembryonic antigen, CEA); C161 -IgGI (anti-normal cross-reacting antigen, NCA); C14 -1gM (anti-Y hapten, Ley) (Price et al., 1987b) Antigen preparations NCRC-1 1 defined antigen preparations were isolated from detergent (Nonidet P-40) solubilised subcellular membranes from breast carcinomas and ovarian mucinous and serous carcinomas by immunoadsorbent chromatography using Sepharose-linked NCRC-l 1 antibodies as previously described (Price et al., 1985 (Price et al., , 1986b . Samples of skim milk and normal urine were also employed as the starting material for NCRC-l 1 defined antigen isolation although detergent was not included in the initial sample solution or washing buffers (Price et al., 1987a) . In all cases, NCRC-11 defined antigens, after elution from the affinity column with 100 mM diethylamine (pH 11.5) and neutralisation with 1 M Tris-HCI (pH 7.6) were dialysed overnight against PBS, centrifuged at 100,000g for 60min and stored at -20C. Subcellular membrane fractions ('extranuclear' membranes, ENM) were prepared from breast and colorectal carcinomas. Normal membrane preparations were isolated from apparently uninvolved tissues, adjacent to the tumour. ENM preparations were obtained as the 100,000g pellets of 600g supernatants of homogenates. Membranes were stored in PBS at -20°C.
CEA was purified from colorectal tumour liver metastases (Krupey et al., 1972) , NCA was isolated by affinity chromatography and Le' bearing glycoproteins were purified from the sputum of a Y hapten positive secretor using affinity chromatography (Price et al., 1986a Purified antibodies (at 10 ytg ml-' in PBS + 0.02% NaN3)
were adsorbed on to the wells of Terasaki microtest plates. After incubation at 5C for 18 h, the wells were aspirated and washed 4 times with washing buffer. On the fourth wash cycle, the plates were incubated with the washing buffer for 1 h in order to block any remaining non-specific binding sites. Aliquots (10 fl) of affinity purified NCRC-1 1 defined antigen, diluted in washing buffer, or washing buffer alone, were added to the wells. After incubation for I h at room temperature, the wells were aspirated and washed 4 times.
'25I-NCRC-1 1 antibody (radiolabelled using 18 MBq 1251 per 25 sg protein according to Jensenius and Williams (1974) was added at I05 c.p.m. 10 sl-' well-' and incubated for 1 h at room temperature. The wells were then aspirated, and washed 6 times, after which the radioactivity in each well was determined.
Immunoblotting NCRC-l 1 defined antigen preparations were diluted 1:1 in SDS PAGE reducing sample buffer and then applied to a 7.5% polyacrylamide gel, with a 4% stacking gel, using an LKB Midget Gel Electrophoresis Apparatus. Electrophoresis was performed at 300 V for 50 min using the discontinuous buffer system of Laemmli (1970) . Electroblotting onto nitrocellulose membranes was performed as described by Towbin et al. (1979) using the Biorad Transblot Apparatus for 20 h at 50 V and 200 mA in 25 mM Tris, 192 mM glycine buffer, pH 8.3, containing 20% methanol. Immunostaining of antigen with NCRC-1 1 and C595 antibodies was performed as previously described (Price et al., 1987a) .
CsCI gradient centrifugation Affinity purified epithelial antigen from urine was subjected to CsCl density gradient centrifugation in a 6 x 16.5 swingout rotor (MSE Scientific Instruments, Crawley, UK) operated at 110,000 g for 70 h at 10°C. The gradient prepared with a starting density of 1.46 g ml' and, after centrifugation, 1 ml fractions were collected from the base of each tube. The density of each fraction was determined gravimetrically and, after dialysis against PBS, fractions were tested for antigenic activity.
Peptide synthesis Synthesis was carried out on a manual solid phase peptide synthesiser (Biolynx 4175), using the continuous Fmoc/polyamide methodology and Ultrosyn A resin (Pharmacia LKB Biotechnology) functionalised at a level of 0.09 mEq g-', was employed. The following amino acid side chain protecting groups were used: histidine, t-butoxycarbonyl (Boc); serine and threonine, t-butyl; arginine, 4-methoxybenzenesulphonyl (Mtr)
Simultaneous deprotection and cleavage of peptide from the resin was performed using either 95% trifluoroacetic acid (TFA) or 5% thioanisole in anhydrous TFA (for P(1-20)). Peptides were purified by HPLC using a gradient elution profile, the eluants being 0. 1% aqueous TFA and 0.1% TFA in 90% aqueous acetonitrile. Table I summarises the results of a comparative analysis of the reactivity of the antibodies C595 and NCRC-1 I with a series of breast carcinomas and normal tissue specimens. With tumours, NCRC-1I staining was variable between tumours and heterogeneous within individual tumours, as has been previously reported (Ellis et al., 1984) . The pattern of reactivity of the C595 antibody was essentially identical although the intensity of staining appeared slightly weaker than with NCRC-1 1. C595 showed no faint non-specific staining of stromal elements, which was occasionally observed with NCRC-l1 antibody.
Results

Immunocytochemical staining of tissues
C595 staining of normal tissues was virtually indistinguishable from that of NCRC-11. The antigen(s) recognised had a highly specific distribution in normal tissues and was confined to the luminal surface of specific epithelia, including the urothelia (Table I) . There was little variability in the level of staining by either antibody when tested against sections from different normal tissue blocks from the same organ, or from different tissue donors. The profile of staining of normal tissues by NCRC-1I antibody corresponded to that originally described in detail by Ellis et al. (1984) . Reactivity of monoclonal antibodies with subcellular membranes The reactivity of C595 and NCRC-11 antibodies with subcellular membranes (ENM, 'extra-nuclear' membranes) from normal and malignant breast tissue was examined using a solid phase radioisotopic antiglobulin assay (Table II) . Both NCRC-1 1 and C595 antibodies showed greater levels of reactivity with tumour ENM compared with ENM derived from normal tissue specimens although overall, the C595 appeared to display a more enhanced descriminatory capacity for tumours. It should be noted that the actual level of reactivity of NCRC-l1 binding to normal ENM (three of four samples) was only slightly elevated above the positivity cut-off value of 1,000 c.p.m. (reactivity score ) 1) and that NCRC-l1 antibody binding to normal tissue ENM was not substantially higher than that of C595 (Table II) . Three control monoclonal antibodies were included in these tests: antibodies against CEA, NCA and the Y-hapten. While the anti-CEA antibody failed to show high binding to either normal or tumour ENM from breast tissues, both anti-NCA and anti-Ley antibodies were in fact discriminatory (this being a consistent unpublished observation in these laboratories).
Neither C595 nor NCRC-11 reacted with normal or tumour colorectal ENM preparations (Table II) , whereas the control antibodies against CEA, NCA and the Y-hapten reacted with these materials, with anti Y-hapten antibodies showing the greatest preferential reactivity towards tumour ENM samples. It is probable that the ENM-antibody binding assay is less sensitive than immunohistology since evidence for NCRC-l antibody binding to colonic tumours has been reported (Ellis et al., 1984 (Figure 1) . No further bands were noted when whole urine was subjected to equivalent analysis.
The urinary mucin antigen (Figure 1 ) was subjected to CsCl density gradient centrifugation and fractions were evaluated for C595 and NCRC-l antibody binding. With both antibodies, the main peak of antibody binding activity was located in a fraction of density around 1.42 g ml' as appropriate for mucinous glycoproteins (Figure 2 ).
Co-expression of C595 and NCRC-JI defined epitopes on epithelial mucins Immunoradiometric assays ('sandwich' tests) were performed to evaluate the expression of the C595 and NCRC-11 defined epitopes on individual epithelial mucin molecules. A series of epithelial mucin antigens were included in this analysis. These were isolated from breast carcinomas (two preparations), ovarian mucinous and serous carcinomas, normal urine (two preparations) and human skim milk. In each case the mucin antigens were purified by their binding to and elution from a Sepharose-NCRC-11 antibody immunoadsorbent column. Each preparation consisted of high molecular weight glycoproteins (>400 kDa) as assessed by SDS PAGE, Western blotting and immunostaining with NCRC-l 1 antibody (Price et al., 1985 (Price et al., , 1986b (Price et al., , 1987a .
As shown in Table IV , these individual antigen preparations were examined for their capacity to 'bridge' C595 antibody adsorbed to the wells of microtest plates (i.e. the 'capture antibody'), and '25I-labelled C595 antibody (the 'tracer antibody'). This formation of complexes was achieved with each antigen, indicating that the C595-defined epitope is a repeated structure of these molecules which may be isolated from both normal body fluids and malignant tissues (Table  IV) . These experiments were extended and each antigen preparation was examined for its capacity to bridge all possible combinations of 'capture' and 'tracer' antibodies using C595 and NCRC-l 1 in both homologous and heterologous IRMA formats. As with C595 antibody tests (first data column in Table IV ), all antigens successfully bridged NCRC-l 1 antibodies when used as both the 'capture' and 'tracer' antibodies (second column in Table IV) . Thus, the NCRC-l 1 defined epitope is also a repeated determinant of the antigens. In heterologous combinations of C595 and NCRC-l 1 antibodies, again all antigens were capable of completing the 'sandwich' complex so that C595 and NCRC-l 1 epitopes are co-expressed upon individual molecules in these epithelial mucin preparations (third and fourth columns in Table IV) .
Unlabelled C595 and NCRC-l 1 antibodies (in hybridoma tissue culture supernatants or as purified antibodies) were examined for their capacity to compete with '25I-labelled NCRC-l 1 antibodies in their binding to urinary epithelial mucin antigen adsorbed to the wells of the microtest plates. As shown in Table V , C595 antibody displayed an inhibitory capacity which was virtually identical to that of unlabelled NCRC-l 1 antibodies. This would indicate that the epitopes for the two antibodies are either identical, or that they are in approximately 00 lAg ml-'. bReactivity scores as in Table II. I1. Production of a 'second generation' monoclonal antibody against a urinary epithelial mucin antigen which has been immuno-affinity purified using an antibody of the 'first generation', has yielded an antibody, C595, of virtually identical specificity to its 'parent' but of the immunoglobulin IgG class rather than being an IgM antibody. In fact, the data in Tables I to V and Figures I and 2 all serve to emphasise the similarities between the two antibodies, C595 and NCRC-l 1. The preliminary survey of antibody reactivity with normal tissues and breast tumours, by immunohistology (Table I) or in subcellular membrane binding assays (Table II) (Tables III to V) .
In Table VII , the binding of urinary mucin to C595 antibody was clearly inhibited by incubation of antibody with the synthetic peptide, P(1 -20), which represents the complete peptide motif which is repeated in epithelial mucins (Gendler et al., 1988) . This would indicate that the epitope for C595 is expressed within the protein core of the mucin. Since C595 failed react with all but the largest peptide, then it might be anticipated that its epitope will be found within the first half of the peptide P(1 -20), within the sequence P D T R P A P G S T (Table VI) .
It appeared not to be possible to modify antigen binding to the antibody NCRC-I 1 by equivalent incubation with the synthetic peptides (Table VII) . This might be taken to suggest that NCRC-1 1 antibody reacts with a non-protein determinant perhaps expressed within the carbohydrate domains of the mucin, rather than in the protein core. Alternatively, synthetic peptides may be less potent inhibitors of multivalent IgM antibodies (e.g. NCRC-1 1) as compared with IgG antibodies such as C595. Most recent results have demonstrated that both C595 and NCRC-11 antibodies bind to peptides which have been synthesised on a solid phase ('tethered' peptides), so that the tests described in Table VII may have been inappropriately designed to reveal the interaction of peptide determinants with NCRC-1 1 antibodies of the IgM class. Studies are in progress to localise the epitopes for C595 and NCRC-I antibodies more precisely within the protein core sequence.
Since the protein core of epithelial mucins consists of tandem repeats of 20 amino acid peptide, this provides an adequate model incorporating the multiple repeats of the C595 and NCRC-11 defined epitopes which are required for the isolated antigen to 'bridge' homologous and heterologous combinations of these two antibodies in IRMAs (Table IV) . Comparably, the close proximity of the peptide regions which are likely to express the epitopes for C595 and NCRC-I I antibodies would explain why C595 antibody was almost as effective as NCRC-11 antibody at inhibiting radiolabelled NCRC-l 1 antibody binding to antigen (Table V) . Evidence is now accumulating that a number of antibodies produced in different laboratories react with the protein core of epithelial mucins rather than with the carbohydrate side chains (e.g. antibodies HMFG-1, HMFG-2, SM-3; Burchell et al., 1987) . Preferential reactivity of anti-core antibodies for tumours may be achieved if the peptide core is more accessible in malignancy-derived mucins. This is feasible since in tumours, aberrant or incomplete glycosylation as well as the action of tumour-associated glycosidases and glycosyltransferases, may well generate core epitopes which are more cryptically expressed (i.e. less accessible) in normal tissue mucins. Staining of tumour tissue sections by NCRC-I1 and C595 antibodies certainly displays wide heterogeneity both within and between specimens, and this may reflect differences in the accessibility or exposure of mucin protein core epitiopes in malignant tissues. Also, staining when observed in normal tissues (and only then, confined to the luminal surface of specialised epithelia) does not appear to attain the same intensity as can be found throughout some, but not necessarily all, tumour tissue sections -thus, the total antigen content or load in breast carcinoma tissue can be considerably greater than in the corresponding normal tissue. If irregular staining of tumour cells is due to incomplete or defective synthesis or carbohydrate chains, then it follows that there may also be epitopes generated in tumour mucin oligosaccharides which are preferentially associated with tumours. The fact remains, however, that with the insight gained upon the nature of the protein core and its antibody defined epitopes, it becomes a feasible objective to design strategies for the production of new antibodies with increased tumour reactivity using more rational approaches than was formerly possible.
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